Targeting Intrinsic and Extrinsic Vulnerabilities for the Treatment of Multiple Myeloma
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting Intrinsic and Extrinsic Vulnerabilities for the Treatment of Multiple Myeloma
Authors
Keywords
-
Journal
JOURNAL OF CELLULAR BIOCHEMISTRY
Volume 118, Issue 1, Pages 15-25
Publisher
Wiley
Online
2016-06-05
DOI
10.1002/jcb.25617
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers
- (2016) Sean W. Harshman et al. Journal of Proteomics
- Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
- (2016) Sagar Lonial et al. LANCET
- Targeting deubiquitinase activity with a novel small-molecule inhibitor as therapy for B-cell malignancies
- (2015) L. F. Peterson et al. BLOOD
- Promising therapies in multiple myeloma
- (2015) G. Bianchi et al. BLOOD
- The role of CD44 in fetal and adult hematopoietic stem cell regulation
- (2015) H. Cao et al. HAEMATOLOGICA
- EZH2 Inhibition Blocks Multiple Myeloma Cell Growth through Upregulation of Epithelial Tumor Suppressor Genes
- (2015) H. Hernando et al. MOLECULAR CANCER THERAPEUTICS
- Tumour exosome integrins determine organotropic metastasis
- (2015) Ayuko Hoshino et al. NATURE
- Transcriptional plasticity promotes primary and acquired resistance to BET inhibition
- (2015) Philipp Rathert et al. NATURE
- Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma
- (2015) Alfred L. Garfall et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting PYK2 mediates microenvironment-specific cell death in multiple myeloma
- (2015) M B Meads et al. ONCOGENE
- The role of CD44 in fetal and adult hematopoietic stem cell regulation
- (2015) H. Cao et al. HAEMATOLOGICA
- An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
- (2015) Ariosto Silva et al. Jove-Journal of Visualized Experiments
- Heat shock proteins in multiple myeloma
- (2015) Lei Zhang et al. Oncotarget
- A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma
- (2014) Robert Z. Orlowski et al. AMERICAN JOURNAL OF HEMATOLOGY
- Pyk2 promotes tumor progression in multiple myeloma
- (2014) Y. Zhang et al. BLOOD
- Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma
- (2014) Sridurga Mithraprabhu et al. Epigenetics
- Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study
- (2014) Shaji K Kumar et al. LANCET ONCOLOGY
- Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents
- (2014) Joel G. Turner et al. SEMINARS IN CANCER BIOLOGY
- p53 Abnormalities and Potential Therapeutic Targeting in Multiple Myeloma
- (2014) P. J. Teoh et al. Biomed Research International
- Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762
- (2013) A. Chaidos et al. BLOOD
- A Preclinical Assay for Chemosensitivity in Multiple Myeloma
- (2013) Z. P. Khin et al. CANCER RESEARCH
- Vaccination with Dendritic Cell/Tumor Fusions following Autologous Stem Cell Transplant Induces Immunologic and Clinical Responses in Multiple Myeloma Patients
- (2013) J. Rosenblatt et al. CLINICAL CANCER RESEARCH
- Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications
- (2013) C C Bjorklund et al. LEUKEMIA
- CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications
- (2013) Y-T Tai et al. LEUKEMIA
- MTI-101 (Cyclized HYD1) Binds a CD44 Containing Complex and Induces Necrotic Cell Death in Multiple Myeloma
- (2013) Anthony W. Gebhard et al. MOLECULAR CANCER THERAPEUTICS
- The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
- (2013) G. Lu et al. SCIENCE
- CRM1 Inhibition Sensitizes Drug Resistant Human Myeloma Cells to Topoisomerase II and Proteasome Inhibitors both In Vitro and Ex Vivo
- (2013) Joel G. Turner et al. Journal of Cancer
- Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma
- (2012) L. Santo et al. BLOOD
- Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma
- (2012) Darrell White et al. CANCER
- A Small Molecule Inhibitor of Ubiquitin-Specific Protease-7 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Bortezomib Resistance
- (2012) Dharminder Chauhan et al. CANCER CELL
- Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma
- (2012) H Tamura et al. LEUKEMIA
- Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27)
- (2012) M. T. McCabe et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications
- (2011) Klaus Podar et al. BRITISH JOURNAL OF HAEMATOLOGY
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
- (2011) Jake E. Delmore et al. CELL
- Marizomib, a Proteasome Inhibitor for All Seasons: Preclinical Profile and a Framework for Clinical Trials
- (2011) B. C. Potts et al. CURRENT CANCER DRUG TARGETS
- Acquisition of Resistance toward HYD1 Correlates with a Reduction in Cleaved 4 Integrin Expression and a Compromised CAM-DR Phenotype
- (2011) M. F. Emmons et al. MOLECULAR CANCER THERAPEUTICS
- NSD2 Links Dimethylation of Histone H3 at Lysine 36 to Oncogenic Programming
- (2011) Alex J. Kuo et al. MOLECULAR CELL
- Initial genome sequencing and analysis of multiple myeloma
- (2011) Michael A. Chapman et al. NATURE
- The therapeutic potential of deubiquitinating enzyme inhibitors
- (2010) Frédéric Colland BIOCHEMICAL SOCIETY TRANSACTIONS
- A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma
- (2010) D. Chauhan et al. BLOOD
- The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma
- (2010) G. W. Xu et al. BLOOD
- The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
- (2010) D. M. Benson et al. BLOOD
- Deubiquitinase Inhibition by Small-Molecule WP1130 Triggers Aggresome Formation and Tumor Cell Apoptosis
- (2010) V. Kapuria et al. CANCER RESEARCH
- Osteoblastogenesis and tumor growth in myeloma
- (2010) Shmuel Yaccoby LEUKEMIA & LYMPHOMA
- An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma
- (2009) Ravi Vij et al. AMERICAN JOURNAL OF HEMATOLOGY
- The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition
- (2009) G. Bianchi et al. BLOOD
- Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma
- (2009) M. Fulciniti et al. BLOOD
- HYD1-induced increase in reactive oxygen species leads to autophagy and necrotic cell death in multiple myeloma cells
- (2009) R. R. Nair et al. MOLECULAR CANCER THERAPEUTICS
- Triptolide alters histone H3K9 and H3K27 methylation state and induces G0/G1 arrest and caspase-dependent apoptosis in multiple myeloma in vitro
- (2009) Fei Zhao et al. TOXICOLOGY
- MYC stimulates EZH2 expression by repression of its negative regulator miR-26a
- (2008) S. Sander et al. BLOOD
- Nitric oxide prodrug JS-K inhibits ubiquitin E1 and kills tumor cells retaining wild-type p53
- (2008) J Kitagaki et al. ONCOGENE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started